Iambic Therapeutics vs Relay Therapeutics (2026)
Both are clinical stage companies whose platforms feed their own pipelines. Iambic, in San Diego, pairs Enchant, a multimodal model predicting preclinical and clinical endpoints whose third generation runs 41 billion parameters across 16 biomedical modalities, with NeuralPLexer3 for protein ligand structure, published at NeurIPS 2025. Every prediction carries an uncertainty estimate that decides which lab experiments run in a weekly cycle. Relay Therapeutics, in Cambridge, Massachusetts, designs drugs around protein motion: its Dynamo platform combines cryogenic electron microscopy, ambient temperature crystallography and long simulations to find pockets that appear only in certain conformations, then uses machine learning to find chemical starting points. Its zovegalisib is in a Phase 3 study. Iambic's published evidence is mostly in its models; Relay's is furthest along in the clinic.
- Enchant v3, released in September 2026, with its size, training data and architecture published across three generations.
- NeuralPLexer3, peer reviewed at NeurIPS 2025.
- Uncertainty on every prediction, used to choose the next experiments.
- Motion based design that looks for binding sites visible only in particular protein conformations.
- Experimental structural biology and long timescale simulation feeding the machine learning.
- Zovegalisib in a Phase 3 study.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Iambic Therapeutics and Relay Therapeutics are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Iambic Therapeutics | Relay Therapeutics |
|---|---|---|
| Primary category | Drug Discovery AI | Drug Discovery AI |
| Founded | 2020 | Not recorded |
| Headquarters | San Diego, California, United States | Cambridge, MA |
| Website | iambic.ai | relaytx.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Iambic Therapeutics
-
Model / architecture
Iambic released Enchant v3, the third generation of the multimodal transformer behind its drug discovery platform.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Clinical stage drug discovery company in San Diego whose platform pairs two named model families with automated laboratories. Enchant is a multimodal transformer that predicts preclinical and clinical endpoints for a target compound profile; its third generation, released in September 2026, runs 41 billion parameters pretrained on 4.5 trillion tokens across 16 biomedical modalities covering more than 6,000 molecular properties, using a mixture of experts architecture, and every prediction carries uncertainty quantification that decides which laboratory experiments to run.
Source: AI Health Index, September 2026
Clinical stage precision medicine company in Cambridge, Massachusetts (Nasdaq: RLAY), built around the Dynamo platform and an approach it calls motion based drug design: proteins move, binding sites appear only in particular conformational states, and a discovery method anchored to static structures misses targets a dynamic one can reach. Dynamo runs in three phases.
Source: AI Health Index, September 2026
Questions buyers ask
How do Iambic Therapeutics and Relay Therapeutics work with the EHR?
No clinical record integration exists: Iambic discovers its own medicines and runs partnered programs on its own platform, and no clinical record system is involved. For a pharma partner the record systems that matter are its research systems: electronic lab notebooks, laboratory information systems, research data platforms and cloud data environments.
No clinical record integration exists: Relay is a drug developer running its platform internally, and no clinical record system is involved. For a pharma or biotech partner the record systems that matter are its research systems: electronic lab notebooks, laboratory information systems, research data platforms and cloud data environments. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are Iambic Therapeutics and Relay Therapeutics priced and sold?
Iambic does not license the platform: it develops its own pipeline and enters multi year discovery collaborations, with agreements announced with AbbVie in September 2026 and Bayer in June 2026, and a partners page describing what a collaboration involves.
Dynamo is not sold: Relay develops its own medicines, and the partnerships it enters bring capability inward rather than licensing the platform out, such as the December 2023 agreement applying a partner's DNA encoded library screening alongside Dynamo against a GPCR target, announced without economics. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How do Iambic Therapeutics and Relay Therapeutics handle patient data?
With Iambic Therapeutics, the only privacy document is a website privacy policy, which by its own terms applies to the company's online activities and to visitors to iambic.ai, covering technical information about a visitor's device, log files and form submissions, with website analytics data unlikely to be kept in identifiable form beyond a year. It says nothing about the material a partner places into the platform.
Relay publishes a privacy policy at relaytx.com/privacy-policy, which may cover the question. No other page states a retention period, a de-identification standard, or what happens to data used in the discovery platform. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Iambic Therapeutics and Relay Therapeutics?
For Iambic Therapeutics, the company has published no efficacy readout with numbers.
With Relay Therapeutics, the publications page lists posters and presentations beside journal articles without printing venues, so the page alone does not show where each item appeared. Trial results to date are interim and no product is approved. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Drug Discovery AI page.
Both records were reviewed on this site in September 2026. Both work through their own pipelines and partnerships, with no list prices, and Relay's privacy policy could not be read for this review.
Ask both how much of each clinical candidate's design came from the platform.